RxDoctor Payments DataLook up a doctor →

Elisabeth Harmeyer

Family · Kenosha, WINPI 1750036117

Payments from drug & device makers

$9,344in general payments, 2019–2025

Across 472 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$795
  • AbbVie$762
  • Axsome Therapeutics, Inc.$582
  • E.r. Squibb & Sons, L.L.C.$559
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$9,344100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,344 in reported general payments places this provider in the 95th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$67,871
Medicare patients
247
Services billed
802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin39$53,772
OzempicSemaglutide29$44,054
MounjaroTirzepatide31$37,559
RybelsusSemaglutide14$20,996
EliquisApixaban20$19,894
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$10,661
FarxigaDapagliflozin Propanediol13$8,417
Albuterol Sulfate HfaAlbuterol Sulfate57$1,673
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,661
Levothyroxine Sodium159$1,228
Atorvastatin Calcium149$1,122
Famotidine49$1,032
Losartan Potassium111$999
CholestyramineCholestyramine (With Sugar)11$945
Pravastatin Sodium61$777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,198$65,05043 claims
Boehringer IngelheimJardiance$23$53,77239 claims
Lilly USA, LLCMounjaro$795$37,55931 claims
PfizerEliquis$350$19,89420 claims
AstraZenecaBreztri Aerosphere, Farxiga$1,511$19,07828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,273 family providers in Wisconsin.

Other family in Kenosha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →